Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

被引：6
|
作者：
Tan, Jiaxiong [1 ,2 ]
Tan, Huo [1 ]
Li, Yangqiu [2 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 5, Dept Hematol, Guangzhou 510700, Peoples R China
[2] Jinan Univ, Inst Hematol, Sch Med, Key Lab Regenerat Med,Minist Educ, Guangzhou 510632, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
基金：
中国国家自然科学基金;
关键词：
TIM-3; Gal-9; Immunotherapy; Hematological malignancies;
D O I：
10.1186/s40164-023-00421-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid leukemia stem cells (LSCs). TIM-3 blockade was shown to have dual effects for directly inhibiting leukemia cells and restoring T cell activation. We summarize several of the latest reports on the role of TIM-3 in immunotherapy for hematological malignancies from the 2022 ASH Annual Meeting (ASH2022).
引用
收藏
页数：4
相关论文
共 50 条
  • [41] CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
    Ruihao Huang
    Qin Wen
    Xi Zhang
    Journal of Hematology & Oncology, 16
  • [42] Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024
    Li, Na
    Sheng, Jianpeng
    Zhu, Hong-Hu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [43] Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
    Jiangxue Hou
    Yufu Li
    Quande Lin
    Experimental Hematology & Oncology, 12
  • [44] Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
    Hou, Jiangxue
    Li, Yufu
    Lin, Quande
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [45] Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
    Zhang, Wenjie
    Li, Sumei
    Long, Jinlan
    Xie, Shufeng
    Wang, Minghui
    Liu, Han
    Xu, Zhenshu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [46] Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting
    Shi, Ting
    Zhu, Hong-Hu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [47] Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
    Jin, Shenhe
    Liu, Yi
    Zhang, Ye
    Zhou, Fengping
    You, Liangshun
    Zhang, Jin
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [48] Therapeutic perspectives for adult soft tissue sarcoma——updates from the 2022 ASCO annual meeting
    Jilong Yang
    Yu Xu
    Yong Chen
    Tao Li
    Xiaowei Zhang
    Tu Hu
    Ruwei Xing
    Yun Yang
    Cancer Biology & Medicine, 2022, (10) : 1496 - 1502
  • [49] Therapeutic perspectives for adult soft tissue sarcoma——updates from the 2022 ASCO annual meeting
    Jilong Yang
    Yu Xu
    Yong Chen
    Tao Li
    Xiaowei Zhang
    Tu Hu
    Ruwei Xing
    Yun Yang
    Cancer Biology & Medicine, 2022, 19 (10) : 1496 - 1502
  • [50] Antibodies targeting LAG-3, TIM-3, KIR cloned from healthy human donors
    Estelles, Angeles
    Stephenson, Robert
    Liu, Keyi
    Lomongsod, Evelene
    Da Ngyen
    Zhzng, Jianzhong
    Yang, Yifan
    Heideker, Manfred
    Kauvar, Lawrence
    Ryser, Stefan
    Gishizky, Mikhail L.
    CANCER RESEARCH, 2016, 76
12345